Alnylam Pharmaceuticals Inc

Stock Chart, Company Information, and Scan Results

$155.94(as of Nov 6, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Alnylam Pharmaceuticals Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$155.94
Ticker SymbolALNY
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees2,500
CountyUSA
Market Cap$20,982.7M
EBIDTA1,033.0M
10-Day Moving Average181.74
P/E Ratio7.90
20-Day Moving Average204.95
Forward P/E Ratio12.59
50-Day Moving Average228.57
Earnings per Share19.80
200-Day Moving Average280.39
Profit Margin148.64%
RSI21.80
Shares Outstanding133.9M
ATR11.35
52-Week High479.79
Volume2,829,700
52-Week Low154.30
Most Recent Support Level156.00
Book Value3,603.9M
Most Recent Resistance Level170.49
P/B Ratio5.97
Upper Keltner230.48
P/S Ratio4.29
Lower Keltner179.42
Debt-to-Equity Ratio0.35
Next Earnings DateUnknown
Cash Surplus-308.7M
Next Ex-Dividend DateUnknown

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals Inc In Our Stock Scanner

As of Nov 08, 2026
example chart graphic
Scan Name: Oversold Stocks Scan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: 52-Week LowScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Undervalued Blue ChipsScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.